Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NASDAQ:ARQT NASDAQ:ELVN NASDAQ:GMTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$4.97-3.1%$5.37$2.03▼$7.18$840.51M1.164.03 million shs2.49 million shsARQTArcutis Biotherapeutics$28.42+2.1%$25.15$13.69▼$31.77$3.48B1.481.28 million shs1.07 million shsELVNEnliven Therapeutics$53.76+1.9%$46.03$14.78▼$55.79$3.21B0.24856,562 shs727,218 shsGMTXGemini Therapeutics$74.12-2.3%$71.92$1.16▼$14.10$3.21B-0.12189,291 shs403,436 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-1.72%-7.90%-6.61%-14.50%+104.38%ARQTArcutis Biotherapeutics+1.79%+1.13%+3.11%+19.54%+87.35%ELVNEnliven Therapeutics-0.40%+2.07%+5.31%+22.71%+148.77%GMTXGemini Therapeutics0.00%-2.67%-0.88%+7.65%+22.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$4.97-3.1%$5.37$2.03▼$7.18$840.51M1.164.03 million shs2.49 million shsARQTArcutis Biotherapeutics$28.42+2.1%$25.15$13.69▼$31.77$3.48B1.481.28 million shs1.07 million shsELVNEnliven Therapeutics$53.76+1.9%$46.03$14.78▼$55.79$3.21B0.24856,562 shs727,218 shsGMTXGemini Therapeutics$74.12-2.3%$71.92$1.16▼$14.10$3.21B-0.12189,291 shs403,436 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-1.72%-7.90%-6.61%-14.50%+104.38%ARQTArcutis Biotherapeutics+1.79%+1.13%+3.11%+19.54%+87.35%ELVNEnliven Therapeutics-0.40%+2.07%+5.31%+22.71%+148.77%GMTXGemini Therapeutics0.00%-2.67%-0.88%+7.65%+22.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.20Hold$15.33208.52% UpsideARQTArcutis Biotherapeutics 2.50Moderate Buy$34.0019.63% UpsideELVNEnliven Therapeutics 2.86Moderate Buy$70.5031.14% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ANNX, ARQT, GMTX, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026ANNXAnnexon CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Underperform7/21/2026ANNXAnnexon Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Underperform$3.007/21/2026ELVNEnliven Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$59.00 ➝ $67.007/20/2026ANNXAnnexon HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.007/17/2026ANNXAnnexon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026ELVNEnliven Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026ANNXAnnexon Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $25.007/13/2026ANNXAnnexon Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight7/9/2026ELVNEnliven Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $64.007/1/2026ELVNEnliven Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $80.006/29/2026ELVNEnliven Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $70.00(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$1.42 per shareN/AARQTArcutis Biotherapeutics$376.07M9.45N/AN/A$1.55 per share18.34ELVNEnliven TherapeuticsN/AN/AN/AN/A$7.74 per shareN/AGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$206.69M-$1.22N/AN/AN/AN/A-101.19%-75.99%8/13/2026 (Estimated)ARQTArcutis Biotherapeutics-$16.14M-$0.03N/A29.60N/A-0.57%-1.41%-0.59%8/5/2026 (Estimated)ELVNEnliven Therapeutics-$103.69M-$1.67N/AN/AN/AN/A-21.04%-20.41%8/12/2026 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/ALatest ANNX, ARQT, GMTX, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026ANNXAnnexon-$0.23N/AN/AN/A$6.50 millionN/A8/12/2026Q2 2026ELVNEnliven Therapeutics-$0.38N/AN/AN/AN/AN/A8/5/2026Q2 2026ARQTArcutis Biotherapeutics$0.09N/AN/AN/A$118.85 millionN/A5/7/2026Q1 2026ANNXAnnexon-$0.30-$0.23+$0.07-$0.23$5.50 millionN/A5/7/2026Q1 2026ELVNEnliven Therapeutics-$0.44-$0.38+$0.06-$0.38N/AN/A5/6/2026Q1 2026ARQTArcutis Biotherapeutics-$0.02-$0.09-$0.07-$0.09$103.68 million$105.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A6.356.35ARQTArcutis Biotherapeutics0.542.682.46ELVNEnliven TherapeuticsN/A40.3240.32GMTXGemini TherapeuticsN/A71.4971.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AARQTArcutis BiotherapeuticsN/AELVNEnliven Therapeutics95.08%GMTXGemini Therapeutics75.42%Insider OwnershipCompanyInsider OwnershipANNXAnnexon10.31%ARQTArcutis Biotherapeutics9.40%ELVNEnliven Therapeutics3.00%GMTXGemini Therapeutics12.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60163.84 million146.95 millionOptionableARQTArcutis Biotherapeutics150125.08 million113.33 millionOptionableELVNEnliven Therapeutics5060.90 million59.08 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableANNX, ARQT, GMTX, and ELVN HeadlinesRecent News About These CompaniesFDA reversals leave investors worrying about the fates of other experimental drugsMarch 6, 2026 | cnbc.comWhat Is Gemini? Everything You Should Know About Google's AI ToolOctober 17, 2024 | cnet.comGoogle Gemini could soon get a lot more useful on your phoneJuly 31, 2024 | androidpolice.comAGemini Review 2024: Is This Crypto Exchange a Gem for Your Investments?July 22, 2024 | businessinsider.comChatGPT vs. Microsoft Copilot vs. Gemini: Which is the best AI chatbot?May 23, 2024 | zdnet.comZGemini Monthly Horoscope: May 2024May 2, 2024 | pedestrian.tvPGoogle's Gemini AI Will Work On Your Pixel 2 XL—Android 10, 11 Devices Now SupportedApril 28, 2024 | techtimes.comTComparing ChatGPT 3.5, Microsoft Bing, and Google Gemini in diagnosing cases of neuro-ophthalmologyApril 17, 2024 | ophthalmologytimes.comOGoogle's public release of Gemini 1.5 should build trust, Deutsche Bank saysApril 17, 2024 | seekingalpha.comGoogle takes down Gemini AI image generator. Here’s what you need to know.February 26, 2024 | washingtonpost.com‘White privilege is f–king real’: Google Gemini product lead’s old tweets allegedly resurface amid ‘woke’ AI image fiascoFebruary 26, 2024 | nypost.comNGoogle Gemini: Everything you need to know about Google's Answer to ChatGPT – Updated December 2023December 9, 2023 | androidheadlines.comAGemini Review 2023: Pros, Cons and How It ComparesNovember 16, 2023 | nerdwallet.comNYesterday's Gemini HoroscopeOctober 5, 2023 | yourtango.comYGemini Tarot Horoscopes: October 2023October 3, 2023 | glamour.comGYearly Gemini Tarot Card ReadingAugust 28, 2023 | yourtango.comYMove over Bard, Google's next big AI product is coming this fallAugust 19, 2023 | androidauthority.comARadar In Space: The Gemini Rendezvous RadarJuly 27, 2023 | hackaday.comHSun Transit in Gemini- The twins love the Sun’s visitJuly 13, 2023 | prokerala.comPSun Transit in Gemini: Sun with Dual energies?July 5, 2023 | prokerala.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANNX, ARQT, GMTX, and ELVN Company DescriptionsAnnexon NASDAQ:ANNX$4.97 -0.16 (-3.12%) Closing price 04:00 PM EasternExtended Trading$4.99 +0.02 (+0.30%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Arcutis Biotherapeutics NASDAQ:ARQT$28.42 +0.58 (+2.08%) Closing price 04:00 PM EasternExtended Trading$28.08 -0.34 (-1.20%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Enliven Therapeutics NASDAQ:ELVN$53.76 +1.02 (+1.93%) Closing price 04:00 PM EasternExtended Trading$53.82 +0.05 (+0.10%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Gemini Therapeutics NASDAQ:GMTX$74.12 -1.74 (-2.29%) As of 07/24/2026Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Stocks Have Soared in 2026—Can They Keep Climbing? Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys? Is the Market Mispricing ServiceNow's AI Future? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
